Mithra Pharmaceuticals S.A.
MITPF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $40,155 | $66,997 | $22,668 | $9,030 |
| % Growth | -40.1% | 195.6% | 151% | – |
| Cost of Goods Sold | $34,164 | $31,563 | $26,150 | $13,330 |
| Gross Profit | $5,991 | $35,434 | -$3,482 | -$4,300 |
| % Margin | 14.9% | 52.9% | -15.4% | -47.6% |
| R&D Expenses | $63,170 | $64,041 | $85,243 | $78,458 |
| G&A Expenses | $22,085 | $14,675 | $12,515 | $15,933 |
| SG&A Expenses | $12,142 | $16,775 | $14,386 | $17,367 |
| Sales & Mktg Exp. | $2,271 | $2,100 | $1,871 | $1,434 |
| Other Operating Expenses | $0 | $28,335 | -$1 | -$1 |
| Operating Expenses | $75,312 | $68,876 | $89,204 | $85,953 |
| Operating Income | -$69,321 | -$33,442 | -$92,686 | -$90,253 |
| % Margin | -172.6% | -49.9% | -408.9% | -999.5% |
| Other Income/Exp. Net | -$92,474 | $19,881 | -$38,462 | -$22,533 |
| Pre-Tax Income | -$161,795 | -$13,561 | -$126,337 | -$112,786 |
| Tax Expense | $11,707 | $46,059 | -$9,462 | -$20,700 |
| Net Income | -$173,502 | -$59,620 | -$116,875 | -$92,086 |
| % Margin | -432.1% | -89% | -515.6% | -1,019.8% |
| EPS | -2.51 | -1.22 | -2.69 | -2.25 |
| % Growth | -105.7% | 54.6% | -19.6% | – |
| EPS Diluted | -2.51 | -1.22 | -2.69 | -2.25 |
| Weighted Avg Shares Out | 69,124 | 49,059 | 43,430 | 40,988 |
| Weighted Avg Shares Out Dil | 69,124 | 49,059 | 43,430 | 40,988 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,745 | $14,029 | $11,765 | $3,503 |
| Interest Expense | $22,899 | $17,031 | $12,115 | $3,562 |
| Depreciation & Amortization | $12,214 | $11,940 | -$7,718 | -$9,049 |
| EBITDA | -$52,771 | $17,462 | -$82,260 | -$80,380 |
| % Margin | -131.4% | 26.1% | -362.9% | -890.1% |